Showing results (21-30 of 48) with videos related to

Sort By:
Pageof 5
Endocrine Journal|August 2, 2021
Efficacy and safety of adding ipragliflozin to insulin in Japanese patients with type 1 diabetes mellitus: a retrospective studyMasashi Shimoda, Akiko Mashiko, Yukino Katakura, et al.
Diabetes, Obesity & Metabolism|July 23, 2024
Effectiveness of switching from dipeptidyl peptidase-4 inhibitor to oral glucagon-like peptide-1 receptor agonist in Japanese participants with type 2 diabetes mellitus: Prospective observational study using propensity score matchingHideyuki Iwamoto, Tomohiko Kimura, Yoshiro Fushimi, et al.
Frontiers in Endocrinology|October 29, 2021
Case Report: A Variety of Immune-Related Adverse Events Triggered by Immune Checkpoint Inhibitors in a Subject With Malignant Melanoma: Destructive Thyroiditis, Aseptic Meningitis and Isolated ACTH DeficiencyYukino Katakura, Tomohiko Kimura, Takashi Kusano, et al.
Internal Medicine (Tokyo, Japan)|August 28, 2024
Nilotinib-induced Diabetes in Japanese Patients with Chronic Myeloid LeukemiaYuichiro Iwamoto, Tomohiko Kimura, Hideyuki Iwamoto, et al.
Frontiers in Endocrinology|August 16, 2023
Immune checkpoint inhibitor-induced hypothyroidism predicts treatment response in Japanese subjectsYuichiro Iwamoto, Tomohiko Kimura, Kazunori Dan, et al.
Diabetes, Obesity & Metabolism|March 20, 2024
Dipeptidyl peptidase-4 inhibitor and sodium-glucose cotransporter 2 inhibitor additively ameliorate hepatic steatosis through different mechanisms of action in high-fat diet-fed miceYuichiro Iwamoto, Tomohiko Kimura, Kazunori Dan, et al.
Scientific Reports|August 17, 2023
Simple standing test without furosemide is useful in the diagnosis of primary aldosteronismYuichiro Iwamoto, Tomohiko Kimura, Mana Ohnishi, et al.
Journal of Diabetes Research|January 15, 2024
Usefulness of Once-Weekly GLP-1 Receptor Agonist Semaglutide on Glycemic Control in Subjects with Type 2 Diabetes Mellitus: Switching from the Same Class Dulaglutide in a Retrospective Observation StudyTomohiko Kimura, Masato Kubo, Kaio Takahashi, et al.
Diabetes, Obesity & Metabolism|September 30, 2024
Tirzepatide, a dual glucose-dependent insulinotropic polypeptide/glucagon-like peptide 1 receptor agonist, exhibits favourable effects on pancreatic β-cells and hepatic steatosis in obese type 2 diabetic db/db miceYuichiro Iwamoto, Tomohiko Kimura, Kazunori Dan, et al.
Scientific Reports|March 29, 2025
Blocking mineralocorticoid signaling with esaxerenone reduces atherosclerosis in hyperglycemic ApoE KO mice without affecting blood pressure and glycolipid metabolismHideyuki Iwamoto, Junpei Sanada, Tomohiko Kimura, et al.
Pageof 5